Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase Ib/II Randomized Clinical Trial of Chemotherapy With Nab-paclitaxel/Gemcitabine/Cisplatin +/- the AXL-inhibitor Bemcentinib for Patients With Metastatic Pancreatic Cancer

Summary

The purpose of this phase Ib/II trial is to evaluate the safety and efficacy of nab-paclitaxel with gemcitabine and cisplatin with or without bemcentinib (BGB324) in patients with metastatic pancreatic cancer.

General Information

NCT#: NCT03649321
Study ID: STU 062018-024
Trial Phase: Phase I/II

Trial Sponsor: Translational Genomics Research Institute (TGen), University of Texas Southwestern Medical Center, BerGenBio
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Cisplatin, Bemcentinib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search